Technical Trends Shift to Mildly Bullish
The primary catalyst for the upgrade stems from a marked improvement in Shilpa Medicare’s technical profile. The technical trend has shifted from a sideways movement to a mildly bullish stance, supported by several key indicators. On a weekly basis, the Moving Average Convergence Divergence (MACD) is bullish, while the monthly MACD remains mildly bearish, suggesting a potential for upward momentum in the near term.
Further technical signals reinforce this positive shift: the weekly Bollinger Bands and On-Balance Volume (OBV) indicators are bullish, indicating increasing buying pressure and volatility expansion in favour of the stock. The Dow Theory readings on both weekly and monthly charts are mildly bullish, adding to the constructive technical narrative. However, some caution is warranted as the daily moving averages are mildly bearish and the weekly Relative Strength Index (RSI) shows bearish tendencies, reflecting short-term overbought conditions or consolidation phases.
Overall, the technical landscape suggests a transition towards a more favourable price action, which has contributed significantly to the revised Mojo Grade from Sell to Hold.
Fundamentals that don't lie! This Small Cap from Trading shows consistent growth and price strength over time. A reliable pick you can truly count on.
- - Strong fundamental track record
- - Consistent growth trajectory
- - Reliable price strength
Valuation Moves from Fair to Expensive
Despite the positive technical momentum, Shilpa Medicare’s valuation grade has shifted from fair to expensive, reflecting a premium pricing relative to its fundamentals and peers. The company currently trades at a price-to-earnings (PE) ratio of 46.34, which is elevated compared to many industry counterparts. Its enterprise value to EBITDA ratio stands at 23.52, while the price-to-book value is 3.54, indicating that investors are paying a significant premium for the stock’s earnings and net asset base.
However, the price-to-earnings-to-growth (PEG) ratio is a notable 0.37, suggesting that the stock’s valuation is supported by strong earnings growth expectations. This is reinforced by the company’s recent financial performance, where net sales have grown by 10.75% in the latest quarter and profits have surged by 124.6% over the past year. The return on capital employed (ROCE) is 8.01%, which, while modest, is an improvement and justifies some of the valuation premium.
When compared with peers such as Ajanta Pharma and Emcure Pharma, which also trade at expensive multiples, Shilpa Medicare’s valuation appears consistent within the sector, albeit on the higher side for a small-cap entity.
Financial Trend Shows Positive Momentum
Shilpa Medicare’s financial trajectory has been encouraging, particularly over the recent quarters. The company has delivered very positive results for ten consecutive quarters, with the latest quarter (Q3 FY25-26) reporting net sales of ₹409.73 crores, marking the highest quarterly sales to date. Operating profit to interest coverage ratio has reached a robust 10.70 times, underscoring strong operational efficiency and debt servicing capability.
Year-to-date returns for the stock stand at an impressive 37.64%, significantly outperforming the Sensex, which has declined by 8.52% over the same period. Over the last one year, Shilpa Medicare has generated a 39.04% return, compared to a negative 3.33% return for the Sensex, highlighting the stock’s resilience and growth potential amid broader market volatility.
Longer-term returns are even more compelling, with a three-year return of 238.19% versus 27.69% for the Sensex, and a five-year return of 101.69% compared to 59.26% for the benchmark index. These figures demonstrate consistent outperformance and validate the company’s growth strategy and execution capabilities.
Quality Assessment Remains Mixed
While the company’s recent financial results and technical indicators have improved, the overall quality grade remains cautious. The average ROCE over the long term is a modest 4.57%, reflecting some weakness in capital efficiency. Net sales and operating profit have grown at annual rates of 9.42% and 12.62% respectively over the past five years, which, although positive, are not exceptional within the pharmaceutical sector.
Majority shareholding remains with non-institutional investors, which may imply limited institutional confidence or lower liquidity. However, the company’s consistent quarterly performance and improving operational metrics provide a foundation for potential quality upgrades in the future.
Holding Shilpa Medicare Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Stock Price and Market Performance
On 7 May 2026, Shilpa Medicare’s stock closed at ₹442.10, up 4.17% from the previous close of ₹424.40. The intraday high was ₹448.70, while the low was ₹423.00. The stock remains below its 52-week high of ₹501.60 but well above its 52-week low of ₹260.00, reflecting a strong recovery and upward momentum over the past year.
The company’s Mojo Score stands at 50.0, with the current Mojo Grade upgraded to Hold from Sell. This reflects a balanced view that recognises the stock’s improved technicals and financial performance, tempered by its expensive valuation and moderate quality metrics.
Outlook and Investor Considerations
Investors should weigh the positive technical signals and strong recent financial results against the premium valuation and mixed quality indicators. The stock’s consistent outperformance relative to the Sensex and sector peers over multiple time horizons is encouraging, but the elevated PE and EV/EBITDA ratios suggest limited margin for valuation expansion.
Given the mildly bullish technical trend and improving fundamentals, Shilpa Medicare is positioned as a Hold for investors seeking exposure to the pharmaceuticals sector with a moderate risk appetite. Caution is advised due to short-term technical bearish signals and the company’s modest long-term capital efficiency.
Overall, the upgrade to Hold reflects a more balanced risk-reward profile, signalling that while the stock is no longer a sell, it may not yet warrant a Buy rating until further improvements in valuation and quality metrics materialise.
Summary of Key Metrics
Current Price: ₹442.10 | PE Ratio: 46.34 | EV/EBITDA: 23.52 | PEG Ratio: 0.37 | ROCE: 8.01% | Dividend Yield: 0.11%
1-Year Return: 39.04% vs Sensex -3.33% | 3-Year Return: 238.19% vs Sensex 27.69%
Conclusion
Shilpa Medicare Ltd’s upgrade to Hold is driven by a combination of improved technical indicators, strong recent financial performance, and a valuation that, while expensive, is supported by growth expectations. Investors should monitor the stock’s technical developments and financial results closely, as further improvements could pave the way for a Buy rating in the future.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
